Redbiotec signed a deal with an antibody company
Redbiotec announced that it has closed a new collaboration agreement with an undisclosed company in the field of antibody generation. The goal of this collaboration is the development of new therapeutic antibodies.
The goal of the collaboration between Redbiotec and the undisclosed company is the development of new therapeutic antibodies using Redbiotec’s VLPs as targets. Under the agreement, the parties will share profit generated by the therapeutic antibodies.
Redbiotec is a privately held Swiss Biopharmaceutical Company, based in Zurich-Schlieren. Founded in 2006 as a spin-off of the ETH Zurich, the company won several awards, including the renowned W.A. De Vigier award.
Redbiotec uses its proprietary rePAX co-expression technology for the efficient generation of multi-component virus-like particles (VLPs) and other protein assemblies. The company entered the field of VLP vaccines in 2008 and currently has a pipeline in the areas of CMV, HPV and Influenza. Besides developing its own prophylactic VLP vaccine pipeline, the company also offers customized solutions in Biologics to selected Partners.
Please login or sign up to comment.
Commenting guidelines